| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03852992 Details | 2023-09-13 Interventional | 2 | 0 | Minoxidil Alopecia Alopecia Areata Androgenetic Al… Male Pattern Ba… Male Pattern Ha… | Study was closed with IRB on 10/22/22 - | |||
| NCT03425006 Details | 2023-09-13 Interventional | 2 | 23 | Pembrolizumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Administrative reasons - | |||
| NCT01093183 Details | 2023-09-13 Interventional | 1/2 | 25 | Cyclophosphamid… Lenalidomide Prostatic Neopl… Adenocarcinoma … Hormone-resista… Recurrent Prost… | study sponsors withdrew support for the study drug. - | |||
| NCT05201001 Details | 2023-09-11 Interventional | 2 | 0 | Carboplatin Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated - | |||
| NCT04099888 Details | 2023-09-11 Interventional | 2 | 41 | Gemcitabine Cholangiocarcin… | Recent results from a Phase 3 study are expected to change the standard of care for patients
with inoperable CCA, rendering the RELEASE study challenging to complete and potentially
inadequate for NDA approval. Due to the early termination of this study, no definitive conclusions can be drawn since an insufficient number of participants was recruited. A reduced statistical analysis was conducted. | |||
| NCT00745316 Details | 2023-09-11 Interventional | 2 | 34 | Adenosine Adenosine A1 Re… Heart Failure Renal Insuffici… | Company Decision - | |||
| NCT05438498 Details | 2023-09-08 Interventional | 3 | 550 | Cilgavimab and … COVID-19 Infections SARS-CoV-2 Infe… | FDA withdrew EUA for AZD7442 - | |||
| NCT05125978 Details | 2023-09-08 Interventional | 2 | 0 | Dipyrone Tramadol Chronic Pain Pain, Chronic | Strategy review - | |||
| NCT04970108 Details | 2023-09-08 Interventional | 3 | 0 | Empagliflozin Telmisartan Diabetes Mellit… Diabetes Mellit… Hypertension Hypertension As… Type II Diabete… | Strategy review - | |||
| NCT04666701 Details | 2023-09-08 Interventional | 2 | 0 | Butylscopolammo… Ketorolac Ketorolac Trome… Scopolamine Acute Pain | Strategy review - | |||
| NCT04593329 Details | 2023-09-08 Interventional | 2 | 0 | Dipyrone Tramadol Acute Pain | Strategy review - | |||
| NCT03363659 Details | 2023-09-08 Interventional | 2 | 15 | Copper Disulfiram Temozolomide Glioblastoma Glioblastoma Mu… | Investigator decision - | |||
| NCT03201250 Details | 2023-09-08 Interventional | 1/2 | 11 | Dexamethasone Multiple Myelom… Neoplasms, Plas… Refractory Mult… Relapsed/Refrac… | Phase I response to treatment was not as expected and the myeloma field in treatment has
changed since initiating the study, so investigators felt the study should not be pursued into
Phase II. - | |||
| NCT05758298 Details | 2023-09-07 Interventional | 1 | 0 | Nicotine Betel Nut Cessa… | Have not received IRB approval. - | |||
| NCT05176288 Details | 2023-09-07 Interventional | 2 | 0 | Avelumab Axitinib Palbociclib Carcinoma Carcinoma, Rena… Advanced Clear … | The overall protocol will be changed in a new amendment, which will be resubmitted under the
new IND. - | |||
| NCT04046107 Details | 2023-09-07 Interventional | 1/2 | 0 | Cemiplimab Hepatitis Hepatitis B Hepatitis B Vir… | Temporarily closed to enrollment - | |||
| NCT02209545 Details | 2023-09-07 Interventional | 4 | 47 | Misoprostol Pyridoxine Vitamin B 6 Hemorrhage Leiomyoma Myofibroma Fibroids | The study was prematurely closed due to low enrollment rates. - | |||
| NCT05835011 2022-501548-14 Details | 2023-09-06 Interventional | 2 | 100 | Decitabine Magrolimab Myelodysplastic… Preleukemia Syndrome | Termination due to discontinuation of magrolimab development in MDS. - | |||
| NCT05552859 2022-001485-35 Details | 2023-09-06 Interventional | 4 | 62 | Insulin Insulin Glargin… Insulin, Globin… Diabetes Mellit… Diabetes Mellit… Renal Insuffici… Renal Impairmen… Type 2 Diabetes… | Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not
related to safety concern. - | |||
| NCT04421378 2021-000080-67 Details | 2023-09-06 Interventional | 1/2 | 74 | Bevacizumab Carmustine Lomustine Temozolomide Glioblastoma Glioblastoma Mu… | Upon further consideration of the existing data and the competitive landscape, Karyopharm
Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this
time. - |